Abdallah Ahmad Suleiman Khatatbeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdallah Ahmad Suleiman Khatatbeh has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Abdallah Abbas
Faculty of Medicine, Al-Azhar University, Damietta, Egypt
1 shared publicationAhmad Al-Tanjy
Jordan Ministry of Health
1 shared publicationAhmed Aldemerdash
Faculty of Medicine, Sohag University, Sohag, Egypt
1 shared publication- Ahmed Farid Gadelmawla
Faculty of Medicine, Menoufia University, Menoufia, Egypt
1 shared publication - Ahmed Negida
Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA
1 shared publication - Ahmed S. A. Osman
Faculty of Medicine, Minia University, Minia, Egypt
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71702
The Neuroprotective Potentials of Dual GIP/GLP1‐RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review
Background: Tirzepatide (TZP), the first approved dual glucagon‐like peptide 1 (GLP‐1)/glucose‐dependent insulinotropic polypeptide (GIP) agonist, has shown neuroprotective effects in preclinical models and early observational studies. This review maps and appraises current preclinical and clinical evidence on TZP's potential neuroprotective effects in neurodegenerative diseases (Alzheimer's and Parkinson's disease), neuroinflammation, cerebrovascular outcomes, neurovestibular disorders, brain tumor response, and idiopathic intracranial hypertension. Methods: PubMed, Scopus, Web of Science, Embase, and Elton B. Stephens Company (EBSCO) were searched through September 30, 2025. Eligible sources included original preclinical or clinical studies reporting neurological or neuroprotective effects of TZP. Quality was assessed using SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Collaborative Approach to Meta‐Analysis and Review of Animal Data from Experimental Studies (CAMARADE) for in vivo studies, toxicological data reliability assessment tool (ToxRTool) for in vitro, Newcastle‐Ottawa scale (NOS) for cohorts, and Joanna Briggs Institute (JBI) for case reports. Results: Twenty‐two studies met inclusion criteria as follows: 11 preclinical investigations, 3 retrospective cohorts, and 8 case reports. Preclinical studies demonstrated mitochondrial stabilization (adenosine triphosphate [ATP] restoration; PINK1/Parkin), anti‐oxidative and anti‐inflammatory signaling, synaptic support (PSD‐95/synaptophysin), and blood–brain barrier reinforcement (claudin‐1), alongside behavioral improvements. Retrospective cohorts reported reduced cerebrovascular and neurodegenerative disease incidence, papilledema, and headaches, though one cohort identified higher risk of central vertigo and vestibular neuronitis. Case reports documented compression neuropathies, autoimmune encephalitis, hypoglycemia‐related seizures, psychiatric reactions, and rhabdomyolysis, most resolving with dose adjustment or discontinuation. Risk‐of‐bias appraisal revealed frequent “unclear” ratings in animal studies, “reliable with restrictions” in vitro, and high NOS scores for cohorts. Conclusions: TZP exhibits biologically plausible neuroprotective mechanisms preclinically. Prospective trials with standardized neurological endpoints, active‐comparator designs, and structured safety monitoring are warranted.
- 17 August 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71702
Open AccessThe Neuroprotective Potentials of Dual GIP/GLP1‐RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review
Background: Tirzepatide (TZP), the first approved dual glucagon‐like peptide 1 (GLP‐1)/glucose‐dependent insulinotropic polypeptide (GIP) agonist, has shown neuroprotective effects in preclinical models and early observational studies. This review maps and appraises current preclinical and clinical evidence on TZP's potential neuroprotective effects in neurodegenerative diseases (Alzheimer's and Parkinson's disease), neuroinflammation, cerebrovascular outcomes, neurovestibular disorders, brain tumor response, and idiopathic intracranial hypertension. Methods: PubMed, Scopus, Web of Science, Embase, and Elton B. Stephens Company (EBSCO) were searched through September 30, 2025. Eligible sources included original preclinical or clinical studies reporting neurological or neuroprotective effects of TZP. Quality was assessed using SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Collaborative Approach to Meta‐Analysis and Review of Animal Data from Experimental Studies (CAMARADE) for in vivo studies, toxicological data reliability assessment tool (ToxRTool) for in vitro, Newcastle‐Ottawa scale (NOS) for cohorts, and Joanna Briggs Institute (JBI) for case reports. Results: Twenty‐two studies met inclusion criteria as follows: 11 preclinical investigations, 3 retrospective cohorts, and 8 case reports. Preclinical studies demonstrated mitochondrial stabilization (adenosine triphosphate [ATP] restoration; PINK1/Parkin), anti‐oxidative and anti‐inflammatory signaling, synaptic support (PSD‐95/synaptophysin), and blood–brain barrier reinforcement (claudin‐1), alongside behavioral improvements. Retrospective cohorts reported reduced cerebrovascular and neurodegenerative disease incidence, papilledema, and headaches, though one cohort identified higher risk of central vertigo and vestibular neuronitis. Case reports documented compression neuropathies, autoimmune encephalitis, hypoglycemia‐related seizures, psychiatric reactions, and rhabdomyolysis, most resolving with dose adjustment or discontinuation. Risk‐of‐bias appraisal revealed frequent “unclear” ratings in animal studies, “reliable with restrictions” in vitro, and high NOS scores for cohorts. Conclusions: TZP exhibits biologically plausible neuroprotective mechanisms preclinically. Prospective trials with standardized neurological endpoints, active‐comparator designs, and structured safety monitoring are warranted.
- Open Access
- 2 February 2026
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 30 (1) , 25
Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Migraine is a chronic, disabling brain disorder. Melatonin, a circadian regulator with anti-inflammatory and antinociceptive actions, has been proposed for migraine prevention. We evaluated the efficacy and safety of melatonin for prophylaxis. Methods: We systematically searched PubMed, Cochrane, Scopus, Embase, and Web of Science (September 29, 2024) for randomised controlled trials (RCTs) comparing melatonin with placebo or other active drugs. Outcomes were analysed as change from baseline to last follow-up using mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI). Results: Nine RCTs ( n = 788) were included. Versus placebo, melatonin reduced attack duration (MD -4.98 h; 95% CI -9.30 to -0.67; p = 0.02), headache days (MD -1.54 days; 95% CI -2.50 to -0.58; p < 0.01), headache severity (MD -2.08; 95% CI -2.91 to -1.26; p < 0.01), and analgesic use (MD -1.38; 95% CI -2.41 to -0.36; p < 0.01). Melatonin also increased the response rate (≥ 50% reduction in monthly headache frequency) (RR 1.38; 95% CI 1.11–1.70; p < 0.01) and improved sleep quality (PSQI: MD -1.64; 95% CI -2.85 to -0.42; p = 0.008) and disability (MIDAS: SMD − 4.07; 95% CI -5.45 to -2.69; p < 0.001). Compared with amitriptyline, melatonin was generally less effective for attack duration and severity, with no consistent advantage on analgesic use or response; however, melatonin showed a more favourable tolerability profile, including lower risk of sleepiness (RR 0.49; 95% CI 0.28–0.87; p = 0.01). Conclusions: Melatonin demonstrates benefits over placebo for reducing migraine burden and improving patient-reported outcomes, with a favourable safety profile. While amitriptyline remains more potent for several efficacy endpoints, melatonin represents a reasonable preventive option, particularly as an adjunct during titration of first-line agents. Further head-to-head trials with standardised dosing and longer follow-up are warranted.
- 2 February 2026
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 30 (1) , 25
Open AccessEfficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Migraine is a chronic, disabling brain disorder. Melatonin, a circadian regulator with anti-inflammatory and antinociceptive actions, has been proposed for migraine prevention. We evaluated the efficacy and safety of melatonin for prophylaxis. Methods: We systematically searched PubMed, Cochrane, Scopus, Embase, and Web of Science (September 29, 2024) for randomised controlled trials (RCTs) comparing melatonin with placebo or other active drugs. Outcomes were analysed as change from baseline to last follow-up using mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI). Results: Nine RCTs ( n = 788) were included. Versus placebo, melatonin reduced attack duration (MD -4.98 h; 95% CI -9.30 to -0.67; p = 0.02), headache days (MD -1.54 days; 95% CI -2.50 to -0.58; p < 0.01), headache severity (MD -2.08; 95% CI -2.91 to -1.26; p < 0.01), and analgesic use (MD -1.38; 95% CI -2.41 to -0.36; p < 0.01). Melatonin also increased the response rate (≥ 50% reduction in monthly headache frequency) (RR 1.38; 95% CI 1.11–1.70; p < 0.01) and improved sleep quality (PSQI: MD -1.64; 95% CI -2.85 to -0.42; p = 0.008) and disability (MIDAS: SMD − 4.07; 95% CI -5.45 to -2.69; p < 0.001). Compared with amitriptyline, melatonin was generally less effective for attack duration and severity, with no consistent advantage on analgesic use or response; however, melatonin showed a more favourable tolerability profile, including lower risk of sleepiness (RR 0.49; 95% CI 0.28–0.87; p = 0.01). Conclusions: Melatonin demonstrates benefits over placebo for reducing migraine burden and improving patient-reported outcomes, with a favourable safety profile. While amitriptyline remains more potent for several efficacy endpoints, melatonin represents a reasonable preventive option, particularly as an adjunct during titration of first-line agents. Further head-to-head trials with standardised dosing and longer follow-up are warranted.
- Open Access
Efficacy and Safety of Glibenclamide in Patients with Post-Ischemic Stroke Cerebral Edema: A Systematic Review and Meta-Analysis
Background: The potential of Glibenclamide to improve functional outcomes in patients with acute ischemic stroke remains controversial. This study aims to evaluate the benefit of Glibenclamide for patients with acute ischemic stroke and at risk of malignant brain edema. Methods: A comprehensive search was undertaken in January 2025 across several electronic databases, including PubMed, Scopus, Cochrane Library, Web of Science, and Embase. RCTs and observational studies were both considered eligible. Data extraction and analysis were done using Review Manager (RevMan) version 5.4. Results: Six studies (four RCTs and two cohort studies) involving 1,244 patients were included; five were eligible for meta-analysis. Glibenclamide significantly reduced MMP-9 levels (MD = – 20.35; 95% CI: –23.65 to –17.04; P < 0.00001; I² = 0%) and midline shift (MD = –2.37 mm; 95% CI: –4.00 to –0.73; P = 0.005; I² = 83%). However, it did not significantly improve modified Rankin Scale scores or reduce the need for decompressive craniotomy. Glibenclamide was associated with a higher risk of hypoglycemia (RR = 3.30; 95% CI: 1.26–8.66; P = 0.02; I² = 0%) and serious adverse events (RR = 1.12; 95% CI: 1.01–1.24; P = 0.04; I² = 0%). No significant differences were observed in other adverse effects. Conclusion: Glibenclamide may reduce inflammation and cerebral edema, but it increases the risk of hypoglycemia and serious adverse events. Given limitations in sample size and study variability, larger high-quality RCTs are needed to confirm efficacy and safety.
Open AccessEfficacy and Safety of Glibenclamide in Patients with Post-Ischemic Stroke Cerebral Edema: A Systematic Review and Meta-Analysis
Background: The potential of Glibenclamide to improve functional outcomes in patients with acute ischemic stroke remains controversial. This study aims to evaluate the benefit of Glibenclamide for patients with acute ischemic stroke and at risk of malignant brain edema. Methods: A comprehensive search was undertaken in January 2025 across several electronic databases, including PubMed, Scopus, Cochrane Library, Web of Science, and Embase. RCTs and observational studies were both considered eligible. Data extraction and analysis were done using Review Manager (RevMan) version 5.4. Results: Six studies (four RCTs and two cohort studies) involving 1,244 patients were included; five were eligible for meta-analysis. Glibenclamide significantly reduced MMP-9 levels (MD = – 20.35; 95% CI: –23.65 to –17.04; P < 0.00001; I² = 0%) and midline shift (MD = –2.37 mm; 95% CI: –4.00 to –0.73; P = 0.005; I² = 83%). However, it did not significantly improve modified Rankin Scale scores or reduce the need for decompressive craniotomy. Glibenclamide was associated with a higher risk of hypoglycemia (RR = 3.30; 95% CI: 1.26–8.66; P = 0.02; I² = 0%) and serious adverse events (RR = 1.12; 95% CI: 1.01–1.24; P = 0.04; I² = 0%). No significant differences were observed in other adverse effects. Conclusion: Glibenclamide may reduce inflammation and cerebral edema, but it increases the risk of hypoglycemia and serious adverse events. Given limitations in sample size and study variability, larger high-quality RCTs are needed to confirm efficacy and safety.